stockrow
Friday 6 November 2026
Export TVTX’s income statement to Excel — free account
Travere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
49.45
0.58
+1.19%
Follow TVTX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.56 | 8.98 | 5.09 | 6.95 | |
P/FCF ratio |
65.82 | 366.95 | 0.00 | 0.00 | |
P/Operating CF |
56.74 | 91.45 | (67.62) | 56.18 | |
P/B ratio |
246.71 | 216.56 | 27.65 | 29.69 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 3,550.82 | |
EV/Sales |
8.76 | 9.17 | 5.18 | 6.92 | |
EV/EBITDA |
0.00 | 269.67 | 208.91 | 0.00 | |
EV/Operating CF |
32.30 | 58.51 | 70.10 | 89.92 | |
EV/FCF |
67.37 | 374.80 | (93.71) | (161.30) | |
Quick Ratio |
2.75 | 3.75 | 2.81 | 2.52 | |
Current Ratio |
3.00 | 4.05 | 3.13 | 2.74 | |
Net Debt/EBITDA |
(2.09) | 13.87 | (4.05) | 0.65 | |
Debt/Assets |
71.15% | 75.41% | 56.21% | 51.51% | |
Debt/Equity |
26.72 | 24.58 | 3.16 | 2.71 | |
Asset Turnover |
0.94 | 0.87 | 0.97 | 0.82 | |
Operating CF/Net income |
(1.88) | (1.67) | 1.09 | 22.23 | |
Capex/Depreciation |
(5.53) | (4.98) | (0.88) | (1.25) | |
Interest Coverage |
(31.82) | 1.85 | (16.05) | (14.14) | |
Research and Development Expense of Revenue |
81.68% | 35.55% | 44.89% | 44.62% | |
Selling, General and Administrative Expense of Revenue |
43.82% | 56.68% | 63.09% | 98.51% | |
Intangible Assets out of Total Assets |
0.19 | 0.16 | 0.20 | 0.19 | |
Share Based Compensation of Revenue |
10.44% | 12.85% | 12.69% | 8.84% | |
Graham Net Nets |
(0.03) | (0.03) | (0.02) | (0.02) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.20%) | (0.79%) | (0.74%) | (0.76%) | |
Free Cash Flow Yield |
1.52% | 0.27% | (1.09%) | (0.62%) | |
Revenue per Share |
2.37 | 1.81 | 1.38 | 1.45 | |
Operating CF per Share |
1.04 | 0.62 | (0.44) | 0.68 | |
Capex per Share |
(0.30) | (0.23) | (0.24) | (0.22) | |
Free Cash Flow per Share |
0.73 | 0.40 | (0.68) | 0.46 | |
Cash per Share |
4.99 | 5.23 | 2.88 | 3.62 | |
Shareholders Equity per Share |
0.24 | 0.26 | 1.07 | 1.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.24 | 0.26 | 1.07 | 1.29 | |
Free Cash Flow |
69.45 | 37.00 | (62.54) | 41.44 | |
Working Capital |
422.53 | 463.12 | 267.24 | 277.66 | |
Capital Expenditures |
(28.75) | (21.07) | (22.18) | (19.24) | |
Net Current Asset Value |
(192.20) | (159.70) | (63.78) | (52.80) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.13 | 0.12 | 0.17 | 0.15 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
95.26 | 59.68 | 60.84 | 53.63 | |
Average Payables |
16.75 | 13.31 | 14.14 | 24.17 | |
Average Inventory |
8.03 | 5.96 | 5.14 | 6.04 | |
Average Assets |
693.41 | 677.33 | 551.99 | 599.66 | |
Average Common Equity |
48.07 | 28.63 | 65.78 | 86.95 |
Columns are period end dates · fundamentals updated 6 Nov 2026